8-K: Arcturus Therapeutics' COVID-19 Vaccine Meets Primary Endpoint in Phase III Booster Study in Japan

Arcturus Therapeutics' bivalent COVID-19 vaccine, Kostaive, successfully met its primary endpoint in a Phase III clinical trial for booster vaccinations in Japan.

Summary

• Meiji Seika Pharma announced that a bivalent version of Arcturus Therapeutics' Kostaive COVID-19 vaccine met the primary endpoint in a Phase III clinical study in Japan.
• The study compared Kostaive to COMIRNATY (Pfizer's) bivalent vaccine in healthy Japanese adults who had previously received three to five mRNA COVID-19 vaccine doses.
• Kostaive demonstrated non-inferiority to COMIRNATY in both geometric mean titer (GMT) ratio and seroresponse rate (SRR) of neutralizing antibodies against the Omicron BA.4/5 strain.
• The study also confirmed the superiority of Kostaive to COMIRNATY against both the Omicron BA.4/5 and Wuhan strains.
• No causally-associated severe or serious adverse events were reported with Kostaive.
• The results support the potential for Meiji Seika Pharma to release updated versions of Kostaive against new variants in 2024.
• The study was conducted in collaboration with Arcturus Therapeutics and under Meiji's partnership with CSL Seqirus for distribution in Japan.

Sentiment

Score: 8

Explanation: The document reports positive clinical trial results, indicating a significant step forward for the company's vaccine program. The lack of serious adverse events and the potential for commercialization contribute to a positive outlook.

Positives

• The Phase III study results for Kostaive were positive, meeting the primary endpoint.
• Kostaive demonstrated non-inferiority and superiority to a leading competitor vaccine in key metrics.
• The vaccine showed a good safety profile with no serious adverse events reported.
• The self-amplifying mRNA technology used in Kostaive has the potential for a more potent immune response.
• The successful trial results pave the way for potential commercial launch and updated versions of the vaccine in 2024.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties.
• Future clinical results may not be predicted by the current data.
• The commercial launch of Kostaive is not guaranteed.
• The company's cash position and expected cash burn are subject to change.
• General business and economic conditions could impact the company's performance.

Future Outlook

The company anticipates the potential commercial launch of Kostaive and the release of updated versions of the vaccine against new variants in 2024. The company also expects to receive payments from CSL.

Management Comments

• Meiji Seika Pharma announced that the bivalent version of Kostaive met the primary endpoint in a Phase III clinical study.
• Arcturus Therapeutics is focused on the development of infectious disease vaccines and therapeutic opportunities within liver and respiratory rare diseases.

Industry Context

This announcement is significant as it demonstrates the potential of self-amplifying mRNA technology in vaccine development and provides a potential alternative to existing mRNA vaccines. The partnership with CSL Seqirus, a major influenza vaccine provider, also positions the vaccine for a strong distribution network in Japan.

Comparison to Industry Standards

• The study compared Kostaive to COMIRNATY (Pfizer's) bivalent vaccine, a leading mRNA vaccine, demonstrating non-inferiority and superiority in certain metrics.
• The use of self-amplifying mRNA technology differentiates Kostaive from standard mRNA vaccines like those from Moderna and BioNTech, potentially offering advantages in dosage and immune response.
• The results are comparable to other successful Phase III vaccine trials, indicating a strong potential for regulatory approval and commercialization.

Stakeholder Impact

• Shareholders may react positively to the successful trial results.
• Employees may be encouraged by the progress of the vaccine program.
• Customers in Japan may benefit from access to a new COVID-19 vaccine.
• CSL Seqirus will benefit from the distribution partnership.
• Creditors may view the positive results as a sign of the company's financial stability.

Next Steps

• Meiji Seika Pharma plans to release updated versions of Kostaive against new variants in 2024.
• The company will likely pursue regulatory approvals for the vaccine in Japan.
• The company will continue to work with CSL Seqirus for distribution of the vaccine.

Key Dates

Keywords

COVID-19 vaccine, mRNA vaccine, self-amplifying mRNA, Kostaive, ARCT-2301, Phase III clinical trial, booster vaccination, Meiji Seika Pharma, CSL Seqirus, immunogenicity, Omicron BA.4/5, Japan